Canada Antifungal Drugs Market Size & Outlook, 2023-2030
Canada antifungal drugs market, 2018-2030 (US$M)
Related Markets
Canada antifungal drugs market highlights
- The Canada antifungal drugs market generated a revenue of USD 569.1 million in 2023 and is expected to reach USD 755.3 million by 2030.
- The Canada market is expected to grow at a CAGR of 4.1% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 569.1 million |
| Market revenue in 2030 | USD 755.3 million |
| Growth rate | 4.1% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Canada accounted for 3.6% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 755.3 million by 2030.
Azoles was the largest segment with a revenue share of 47.53% in 2023. Horizon Databook has segmented the Canada antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
Key players in the country are engaged in strategic initiatives, such as new product launches and collaborative partnerships. Players are launching new and generic versions of drugs in the country to take advantage of the lucrative market.
For instance, in May 2019, Avir Pharma and Basilea announced a partnership to launch Cresemba in Canada. Similarly, in January 2021, Sandoz launched a generic version of Posaconazole in Canada.
The launch of new as well as generic products demonstrates the high demand for antifungal drugs, thereby making business for key players in the country.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada antifungal drugs market size, by drug class, 2018-2030 (US$M)
Canada Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
